PF方案新辅助化疗用于宫颈癌的近期疗效观察

Therapeutic observation of the curative effect of PE scheme-neoadjuvant chemotherapy on cervical cancer

目的探讨术前新辅助化疗（NACT）对早期巨块型及局部晚期宫颈癌（L，AcC）的近期疗效和安全性。方法选择病理确诊的Ib2～Ⅱb期宫颈癌患者49例，采用顺铂＋5-氟尿嘧啶静脉化疗一个疗程，于化疗结束后10～14d行广泛性子宫切除＋盆腔淋巴结清扫术。观察患者病灶大小的改变、化疗毒副反应、术中情况等，评价新辅助化疗在宫颈癌治疗中的作用及安全性。结果I临床近期有效率达87．7％，手术切除率达98．0％，所有患者切缘无肿瘤残留。化疗毒副反应轻微，患者能较好耐受。结论术前新辅助化疗可有效缩小病灶，提高宫颈癌的近期疗效，为根治性手术创造条件。

Objective To explore the near future curative effect and safety of neoadjuvant chemotherapy on local advanced stage cervical cancer. Methods Forty-nine patients whose patholo- gy diagnosis were I b2- IIb were collected, and received 1 course of treatment with DDP and 5-Fu （DDP 75 mg/m2 ＋ 5-fu 750 mg/（m2- d） × 5 d）, 10-14 d after chemotherapy all patients received catholicity uterectomy and pelvic cavity lymphaden scavenge. This was to evaluate the effect and safety of NACT on LACC by observing the change of focus of infection, the side effect of chemotherapy, and the condition in operation. Results The clinic efficacy rate in near future reached 87.7 %, and the rate of exairesis reached 98.0 %. All patients had little chemotherapy side effect and no tumor remained. Conclusion Preoperative NACT is effective in diminishing tumor size, and increasing the effect of near future in cervical cancer. The patients can have better toler- ance, which creates condition for radical hysterectomy.